Search

Displaying results 791 - 800 of 4588 in total
  1. Drug

    Brilliant blue G

    go.drugbank.com/drugs/DB15594
    Approved

    It was approved by the FDA for ophthalmic use on December 20, 2019.[L10830] … [A188841,A188844] This membrane is thin and translucent, making it difficult to identify during eye surgeries that require high levels of visual accuracy.

  2. Drug

    Mepolizumab

    go.drugbank.com/drugs/DB06612
    ApprovedInvestigational

    The pathogenesis of eosinophilia is complex, but IL-5 is recognized as a key cytokine involved in the differentiation, recruitment, activation, and prolonged survival of eosinophils in peripheral tissue … Mepolizumab was first approved by the FDA on November 4, 2015, as an add-on therapy for severe asthma and marketed under the brand name Nucala by GlaxoSmithKline.

  3. Drug

    Linerixibat

    go.drugbank.com/drugs/DB11729
    ApprovedInvestigational

    [A275481, A275482] On March 19, 2026, linerixibat was approved by the FDA for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC). … [A275482, L56120] Linerixibat functions by interrupting the enterohepatic circulation of these bile acids, thereby reducing their systemic concentration.[A275482]

  4. Drug

    Padeliporfin

    go.drugbank.com/drugs/DB15575
    ApprovedInvestigational

    [A244699] Padeliporfin was first approved by the European Commission on November 10, 2017, for the treatment of low-risk prostate cancer in adults meeting certain clinical criteria.[L39799]

  5. Drug

    Choline magnesium trisalicylate

    go.drugbank.com/drugs/DB01401
    Approved

    Trisalicylate significantly reduces methotrexate renal clearance, displacing methotrexate from protein, increasing the fraction unbound by 28% [A19653, A19654].

  6. Drug

    Pipotiazine

    go.drugbank.com/drugs/DB01621
    ApprovedInvestigationalWithdrawn

    However, it produces a high incidence of extra pyramidal reactions. It is used for the maintenance treatment of chronic non-agitated schizophrenic patients.

  7. Drug

    Eletriptan

    go.drugbank.com/drugs/DB00216
    ApprovedInvestigational

    Eletriptan is a second generation triptan drug developed by Pfizer Inc for the treatment of migraine headaches.

  8. Drug

    Diltiazem

    go.drugbank.com/drugs/DB00343
    ApprovedInvestigational

    It works through various mechanisms of action, but it primarily works by inhibiting the calcium influx into cardiac and vascular smooth muscle during depolarization. … Approved in 1982 by the FDA, it is a member of the non-dihydropyridine calcium channel blockers drug class.

  9. Drug

    Amlodipine

    go.drugbank.com/drugs/DB00381
    ApprovedInvestigational

    Amlodipine is commonly used in the treatment of high blood pressure and angina. … Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called _dihydropyridine calcium channel blockers_.

  10. Drug

    Prednisolone acetate

    go.drugbank.com/drugs/DB15566
    ApprovedInvestigationalVet approved

    Prednisolone acetate is a [prednisolone] molecule bound to an acetate functional group by an ester bond.[L9449] Prednisolone acetate was granted FDA approval in 1955.[L9449]